The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial

Jing Pu; Qin Yu; Zhifang Yin; Ying Zhang; Xueqi Li; Qiongzhou Yin; Hongbo Chen; Runxiang Long; Zhimei Zhao; Tangwei Mou; Heng Zhao; Shiyin Feng; Zhongping Xie; Lichun Wang; Zhanlong He; Yun Liao; Shengtao Fan; Ruiju Jiang; Jianfeng Wang; Lingli Zhang; Jing Li; Huiwen Zheng; Pingfang Cui; Guorun Jiang; Lei Guo; Mingjue Xu; Huijuan Yang; Shan Lu; Xuanyi Wang; Yang Gao; Xingli Xu; Linrui Cai; Jian Zhou; Li Yu; Zhuo Chen; Chao Hong; Dan Du; Hongling Zhao; Yan Li; Kaili Ma; Yunfei Ma; Donglan Liu; Shibao Yao; Changgui Li; Yanchun Che; Longding Liu; Qihan Li

The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial

Vaccine (2021) - Comments
pubmed: 33875266 doi: 10.1016/j.vaccine.2021.04.006 issn: 0264-410x issn: 1873-2518

Jing Pu, Qin Yu, Zhifang Yin, Ying Zhang, Xueqi Li, Qiongzhou Yin, Hongbo Chen, Runxiang Long, Zhimei Zhao, Tangwei Mou, Heng Zhao, Shiyin Feng, Zhongping Xie, Lichun Wang, Zhanlong He, Yun Liao, Shengtao Fan, Ruiju Jiang, Jianfeng Wang, Lingli Zhang